First Patient Dosed in CatalYm’s Phase IIb Visugromab Trial

First patient dosed in CatalYm’s Phase IIb visugromab trial

CatalYm has dosed the first patient in its Phase IIb GDFATHER-HCC-01 clinical trial, assessing visugromab along with chemoimmunotherapy as a second-line treatment for patients with unresectable or metastatic HCC.The post First patient dosed in CatalYm’s Phase IIb visugromab trial appeared first on Clinical Trials Arena.

CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma

Study targets patients with unresectable or metastatic hepatocellular carcinoma who have progressed following first-line anti-PD-(L)1-based therapy Initiation of the third Phase 2b study of visugromab, expanding development into hepatocellular carcinoma following first and second-line NSCLC programs MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm today announced that the first patient has been dosed in the GDFATHER-HCC-01 trial (NCT07219459). m…

CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment

Study expands development of the antibody into hepatocellular carcinoma